Cost-effectiveness Analysis of second-Line and third-Line antidiabetic Drugs In Tyep 2 Diabetes- an Empirical, population-based observational Study From Taiwan
May 1, 2015, 00:00 AM
10.1016/j.jval.2015.03.360
https://www.valueinhealthjournal.com/article/S1098-3015(15)00417-9/fulltext
Section Title :
Diabetes/Endocrine Disorders
Section Order :
1457
First Page :
A61
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)00417-9&doi=10.1016/j.jval.2015.03.360